Clinicians & health systems
Health systems and clinicians interested in early detection and monitoring.
About Toby Oncology
Making early cancer detection accessible
Toby Oncology has developed an AI-powered, urine-based platform designed to accurately detect cancers at stages 1 and 2, using simple, scalable workflows that can fit into real-world labs and everyday care.
We’re combining proven science, real-world clinical collaboration, and practical design to bring multi-cancer early detection into everyday care.
Early should mean early
Our mission is to make early multi-cancer detection accurate, accessible, affordable, and easier
—so more cancers are found at stages 1 and 2, when treatment can be most effective and lives can be changed.
Toby Oncology was founded by scientists, clinicians, and entrepreneurs who believed there had to be a better way—one that could read the body’s early chemical signals from something as simple as urine and bring multi-cancer early detection into everyday care.
We imagine a world where checking for multiple cancers is as routine as a blood pressure check: quick, non-invasive, and built into the way healthcare already works—not a rare, specialty experience reserved for a few.
A NEW APPROACH NEEDED
Why early detection can’t wait
Nearly 3 billion people worldwide are over 40—yet we still don’t have simple, multi-cancer early detection, and most of the deadliest cancers have no routine screening.
Issue 1
Most deadly cancers aren’t screened for
Only five cancers have routine screening today. Cancers that cause roughly 70% of deaths still don’t have a recommended test or simple way to be found early.
Issue 2
Late diagnosis slashes survival
When cancer is found after it has spread, five-year survival can fall to around 20%. Found earlier, survival can be several to tens of times higher, depending on the cancer type.
Issue 3
Current tests are hard to scale
Existing testing options are invasive, complex, often inaccurate at early stages, and expensive. They’re difficult to deploy broadly and don’t fit smoothly into everyday care.
Pancreatic cancer spotlight
Why finding pancreatic cancer early matters
For pancreatic cancer, five-year survival is ~31.7% when found at stage 1—but only ~0.5% at stage 4 (~63× survival advantage for the earliest stage). In an internal multi-cancer study, the Toby platform detected pancreatic cancer at early stages, underscoring the potential impact of earlier detection in one of the deadliest cancers.
WHAT WE’VE BUILT
A urine-based, multi-cancer detection platform
Toby Oncology has developed a urine-based platform that reads tiny chemical signals released by the body and uses AI to look for patterns linked to cancer, especially in its earliest stages. Our approach is designed to work with samples clinics already collect and the equipment labs already run.
Early – Built to detect cancers at stages 1 and 2, before symptoms appear.
Easy – Uses a simple urine sample collected during a routine visit, with no new procedure.
Practical – Fits into existing lab equipment and workflows to support routine care at scale.
Affordable – Keeps per-test costs low so multi-cancer screening is broadly accessible.
WHERE WE ARE TODAY
From development to validation
Our platform is ready to support clinical trials and research today, while in parallel we pursue broad-based clinical validation. Early internal data and external studies are helping us understand how the platform performs at stages 1 and 2 across multiple cancer types.
-
1
Academic literature review: 30+ peer-reviewed studies supporting urine-based VOC biomarkers and related science.
-
2
Early internal studies across hundreds of patient samples and multiple cancer types.
-
3
External blinded prostate cancer study led by a leading academic institution, demonstrating strong performance compared to current standards.
-
4
FDA Breakthrough Device Designation for a multi-cancer early detection (MCED) test across the 10 most common cancers.
-
5
Growing portfolio of patents covering biomarkers, analysis methods, and the platform.
Leadership and advisors
Our team brings experience from oncology, diagnostics, digital health, and building high-growth healthcare companies.
Matthew Collier
CEO, Board Member
Serial CEO across 5 companies, tier-1 consulting global practice head, diagnostics depth.
Dan Collins
Executive Chairman
Founder/CEO of Genesis Healthcare, Cancer and diagnostics depth.
Clark Golestani
Board Member
C Sensei Group
Former President, Emerging Businesses & Global CIO at Merck, Advisor to New Mountain Capital and Advent.
Partner with us on what’s next for early detection
Clinicians, health systems, labs, life sciences teams, and investors, connect with us to explore trials, research, and partnership opportunities.
While available for clinical trials and research, Toby Oncology’s platform is not yet broadly available for routine clinical use or population-wide screening. Performance metrics and indications described on this site are based on current studies and may evolve as additional data become available.